0
ERRATUM
Erratum
Psychiatric News
Volume 41 Number 5 page 20-20

It was incorrectly reported in the January 20 issue that the methylphenidate skin patch was deemed approvable by an FDA panel for the treatment of attention-deficit/hyperactivity disorder in adults as well as children aged 6 to 12. In fact, approval was sought and obtained for use only in children aged 6 to 12. The patch was developed by Noven Pharmaceuticals and will be marketed jointly by Noven and Shire Pharmaceuticals under the trade name Daytrana. ▪

Interactive Graphics

Video

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles
Articles